Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Morairty, Stephen R ^a   Revel, Florent G ^b   Malherbe, Pari ^b   Moreau, Jean Luc ^b   Valladao, Daniel ^a   Wettstein, Joseph G ^b   Kilduff, Thomas S ^a   Borroni, Edilio ^b  

^a SRI INTERNATIONAL   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 1 (6,8 DIFLUORO 2 METHYL 4 QUINOLINYL) 3 (4 DIMETHYLAMINOPHENYL)UREA; 1 (6,8 DIFLUORO 2 METHYLQUINOLIN 4 YL) 3 (4, DIMETHYLAMINOPHENYL)UREA; ALMOREXANT; N [ETHYL 2 [(6 METHOXYPYRIDIN 3 YL)(TOLUENE 2 SULFONYL)AMINO] N PYRIDIN 3 YL METHYLACETAMIDE]; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; 1 (2 METHYLBENZOXAZOL 6 YL) 3 (1,5)NAPHTHYRIDIN 4 YL UREA; 1-(2-METHYLBENZOXAZOL-6-YL)-3-(1,5)NAPHTHYRIDIN-4-YL UREA; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMINOPYRIDINE DERIVATIVE; BENZOXAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; G PROTEIN COUPLED RECEPTOR; N ETHYL 2 ((6 METHOXY PYRIDIN 3 YL) (TOLUENE 2 SULPHONYL)AMINO) N PYRIDIN 3 YLMETHYL ACETAMIDE; N-ETHYL-2-((6-METHOXY-PYRIDIN-3-YL)-(TOLUENE-2-SULPHONYL)AMINO)-N-PYRIDIN-3-YLMETHYL-ACETAMIDE; NEUROPEPTIDE RECEPTOR; OREXIN RECEPTORS; SULFONAMIDE; UREA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HYPNOSIS; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; RECEPTOR POTENTIAL; REM SLEEP; SLEEP INDUCTION; SLEEP STAGE; SLEEP TIME; SLEEP WAKING CYCLE; STEADY STATE; WAKEFULNESS; ANIMAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; SLEEP; SPRAGUE DAWLEY RAT;

RATTUS;

AMINOPYRIDINES; ANIMALS; BENZOXAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; GABA AGONISTS; MALE; PHENYLUREA COMPOUNDS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; SLEEP; SULFONAMIDES; UREA;

EID: 84863614156     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039131     Document Type: Article

References (64)

1. de Lecea L, Kilduff TS, Peyron C, Gao X-B, Foye PE, et al. (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95: 322-327.
2. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, et al. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92: 573-585.
3. Lin L, Faraco J, Li R, Kadotani H, Rogers W, et al. (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98: 365-376.
4. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, et al. (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98: 437-451.
5. Haynes AC, Jackson B, Chapman H, Tadayyon M, Johns A, et al. (2000) A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul Pept 96: 45-51.
6. Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, et al. (2001) SB-334867-A: the first selective orexin-1 receptor antagonist. Br J Pharmacol 132: 1179-1182.
7. Hirose M, Egashira S, Goto Y, Hashihayata T, Ohtake N, et al. (2003) N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg Med Chem Lett 13: 4497-4499.
8. Kilduff TS, Peyron C, (2000) The hypocretin/orexin ligand-receptor system: Implications for sleep and sleep disorders. Trends Neurosci 23: 359-365.
9. Sakurai T, (2007) The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 8: 171-181.
10. Siegel JM, (2004) Hypocretin (orexin): role in normal behavior and neuropathology. Annu Rev Psychol 55: 125-148.
11. Adamantidis A, de Lecea L, (2009) The hypocretins as sensors for metabolism and arousal. J Physiol 587: 33-40.
12. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, et al. (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30: 345-354.
13. Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, et al. (2003) Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 38: 701-713.
14. Samson WK, Taylor MM, Ferguson AV, (2005) Non-sleep effects of hypocretin/orexin. Sleep Med Rev 9: 243-252.
15. Bingham S, Davey PT, Babbs AJ, Irving EA, Sammons MJ, et al. (2001) Orexin-A, an hypothalamic peptide with analgesic properties. Pain 92: 81-90.
16. Kajiyama S, Kawamoto M, Shiraishi S, Gaus S, Matsunaga A, et al. (2005) Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally-administered orexins in diabetic neuropathic pain model rats. Brain Res 1044: 76-86.
17. Mobarakeh JI, Takahashi K, Sakurada S, Nishino S, Watanabe H, et al. (2005) Enhanced antinociception by intracerebroventricularly and intrathecally-administered orexin A and B (hypocretin-1 and-2) in mice. Peptides 26: 767-777.
18. Xie X, Wisor JP, Hara J, Crowder TL, Lewinter R, et al. (2008) Hypocretin/orexin and nociceptin/orphanin FQ coordinately regulate analgesia in a mouse model of stress-induced analgesia. J Clin Invest 118: 2471-2481.
19. Winsky-Sommerer R, Yamanaka A, Diano S, Borok E, Roberts AJ, et al. (2004) Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating the stress response. J Neurosci 24: 11439-11448.
20. Narita M, Nagumo Y, Hashimoto S, Narita M, Khotib J, et al. (2006) Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci 26: 398-405.
21. Harris GC, Wimmer M, Aston-Jones G, (2005) A role for lateral hypothalamic orexin neurons in reward seeking. Nature 437: 556-559.
22. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A, (2006) Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 49: 589-601.
23. Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, et al. (2005) Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci U S A 102: 19168-19173.
24. Johnson PL, Truitt W, Fitz SD, Minick PE, Dietrich A, et al. (2010) A key role for orexin in panic anxiety. Nat Med 16: 111-115.
25. Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, et al. (2012) Pharmacological characterization of MK-6096- A dual orexin receptor antagonist for insomnia. Neuropharmacology 62: 978-987.
26. Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, et al. (2011) Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet 25: 52-61.
27. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, et al. (2007) Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 13: 150-155.
28. Di Fabio R, Pellacani A, Faedo S, Roth A, Piccoli L, et al. (2011) Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorg Med Chem Lett 21: 5562-5567.
29. Whitman DB, Cox CD, Breslin MJ, Brashear KM, Schreier JD, et al. (2009) Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats. ChemMedChem 4: 1069-1074.
30. Coleman PJ, Schreier JD, Roecker AJ, Mercer SP, McGaughey GB, et al. (2010) Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat. Bioorg Med Chem Lett 20: 4201-4205.
31. Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, et al. (2010) Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methy l-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 53: 5320-5332.
32. Dugovic C, Shelton JE, Aluisio LE, Fraser IC, Jiang X, et al. (2009) Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther.
33. Gozzi A, Turrini G, Piccoli L, Massagrande M, Amantini D, et al. (2011) Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS One 6: e16406.
34. Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, et al. (2004) Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 141: 340-346.
35. McAtee LC, Sutton SW, Rudolph DA, Li X, Aluisio LE, et al. (2004) Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg Med Chem Lett 14: 4225-4229.
36. Smith MI, Piper DC, Duxon MS, Upton N, (2003) Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci Lett 341: 256-258.
37. Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, et al. (2009) Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX receptor. Br J Pharmacol 156: 1326-1341.
38. Koberstein R, Fischli W, Clozel M, Aissaoui H, Weller T, (2005) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. World patent: WO 2005118548.
39. Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, et al. (2008) Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther 324: 948-956.
40. Morairty SR, Hedley L, Flores J, Martin R, Kilduff TS, (2008) Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats. Sleep 31: 34-44.
41. Ballard TM, Knoflach F, Prinssen E, Borroni E, Vivian JA, et al. (2009) RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors. Psychopharmacology (Berl) 202: 207-223.
42. Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM, (1998) Distribution of orexin receptor mRNA in the rat brain. FEBS Lett 438: 71-75.
43. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, et al. (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435: 6-25.
44. Akanmu MA, Honda K, (2005) Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats. Brain Res 1048: 138-145.
45. Mieda M, Hasegawa E, Kisanuki YY, Sinton CM, Yanagisawa M, et al. (2011) Differential roles of orexin receptor-1 and-2 in the regulation of non-REM and REM sleep. J Neurosci 31: 6518-6526.
46. Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, et al. (2001) Fos expression in orexin neurons varies with behavioral state. J Neurosci 21: 1656-1662.
47. Yoshida Y, Fujiki N, Nakajima T, Ripley B, Matsumura H, et al. (2001) Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 14: 1075-1081.
48. Norman PS, (1985) Newer antihistaminic agents. J Allergy Clin Immunol 76: 366-368.
49. Kaliner MA, (1992) Nonsedating antihistamines: pharmacology, clinical efficacy and adverse effects. Am Fam Physician 45: 1337-1342.
50. Snyder SH, Snowman AM, (1987) Receptor effects of cetirizine. Ann Allergy 59: 4-8.
51. Baker DE, (2007) Loperamide: a pharmacological review. Rev Gastroenterol Disord 7: S11-18.
52. Emerich DF, Snodgrass P, Pink M, Bloom F, Bartus RT, (1998) Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport (RMP-7). Brain Res 801: 259-266.
53. Schinkel AH, Wagenaar E, Mol CA, van Deemter L, (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517-2524.
54. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ, (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68: 231-237.
55. Linnet K, Ejsing TB, (2008) A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol 18: 157-169.
56. Thuerauf N, Fromm MF, (2006) The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur Arch Psychiatry Clin Neurosci 256: 281-286.
57. Coleman PJ, Schreier JD, Cox CD, Breslin MJ, Whitman DB, et al. (2012) Discovery of [(2R,5R)-5-{[(5-Fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-m ethyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): A Dual Orexin Receptor Antagonist with Potent Sleep-Promoting Properties. ChemMedChem.
58. Saper CB, Chou TC, Scammell TE, (2001) The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 24: 726-731.
59. Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, et al. (2003) Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 38: 715-730.
60. Kilduff TS, (2005) Hypocretin/orexin: maintenance of wakefulness and a multiplicity of other roles. Sleep Med Rev 9: 227-230.
61. Kuwaki T, (2008) Orexinergic modulation of breathing across vigilance states. Respir Physiol Neurobiol 164: 204-212.
62. Kuwaki T, Li A, Nattie E, (2010) State-dependent central chemoreception: A role of orexin. Respir Physiol Neurobiol.
63. Kuwaki T, Zhang W, (2010) Orexin neurons as arousal-associated modulators of central cardiorespiratory regulation. Respir Physiol Neurobiol.
64. Nattie E, Li A, (2010) Central chemoreception in wakefulness and sleep: evidence for a distributed network and a role for orexin. J Appl Physiol 108: 1417-1424.